CASE REPORT

Inactivated COVID-19 vaccine triggering hemophagocytic lymphohistiocytosis in an immunocompetent adult - A case report

Saad Nasir, Saqib Raza Khan*, Rodaba Iqbal, Alizah Pervaiz Hashmi, Munira Moosajee, Noreen Nasir

Aga Khan University Hospital, Karachi, Pakistan

*Corresponding author
Saqib Raza Khan
Aga Khan University Hospital, Karachi, Pakistan
Email: saqib.raza31@yahoo.com

Author information:
Received: January 22, 2022
Revised: February 10, 2022
Accepted: March 11, 2022
ABSTRACT

**Background and aim:** Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome that is induced by hyper-activated macrophages, cytotoxic T cells, and reduced natural killer (NK) cell activity. A 46-year-old gentleman presented to us with complaints of intermittent fever for the past two weeks associated with fatigue along with oral ulcers and skin rashes which resolved spontaneously. These symptoms started after he received the second dose of the BBIP-CorV COVID-19 vaccine. His complete blood picture showed pancytopenia. A detailed infectious disease workup was unrevealing; however, his bone marrow biopsy revealed increased histiocyte activity, with some showing hemophagocytosis and dysplasia. Immunohistochemistry (IHC) profile demonstrated strong CD 68 positivity. Further investigations showed raised serum ferritin and fasting triglyceride levels. He was immediately started on dexamethasone acetate at a dose of 10 mg/m2, after which his clinical symptoms, as well as his blood parameters, improved remarkably. This is the first documented case in Pakistan.

**Conclusion:** The data from clinical trials support the general safety profile of inactivated COVID-19 vaccines. We endorse its mass implementation. However, we believe that robust data needs to be generated to evidence any adverse events, especially those with serious outcomes. Physicians should be aware of inactivated COVID-19 vaccine as a possible trigger for HLH and start prompt treatment, resulting in favorable outcomes.

**Relevance for patients:** The presentation of HLH may vary and can present in an immunocompetent patient with no underlying risk factor. HLH should be kept in differentials when a patient presents with pancytopenia with a recent history of receiving COVID-19 vaccination. Steroids play a major role in the treatment of HLH, and definitive diagnosis and early treatment improve clinical outcomes.

**Keywords:** Hemophagocytic Lymphohistiocytosis (HLH), COVID-19 Vaccine, Immunohistochemistry
1. INTRODUCTION

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by hyper-activated macrophages, cytotoxic T cells, and reduced NK cell activity. The primary form, caused by familial genetic mutations affecting immune regulation, is most commonly found in children. In contrast, the secondary form, the acquired one, is observed mostly in adults. Secondary HLH is multifactorial, triggered by infections or malignancies but may also be induced by autoimmune disorders, in which case it is called macrophage activation syndrome (MAS) [1]. The list of potential documented etiologies for secondary HLH includes infections (Epstein-Barr virus, herpes simplex virus, cytomegalovirus, avian influenza), rheumatologic diseases (rheumatoid arthritis, systemic lupus erythematosus, Kawasaki syndrome), malignancy (natural killer cell leukemia, peripheral T-cell lymphoma, B-cell lymphoma), acquired immune deficiency states (after organ transplantation), and drugs [2].

The initial diagnostic guidelines of HLH were proposed by Henter et al. in 1991, which were further updated in 2004. With a mortality rate of approximately 40%, the HLH patients may present with progressive multi-organ failure resulting in adverse outcomes [3]. Hence, the prognosis of secondary HLH is dismal if not managed early. Liederman et al. reported secondary HLH cases associated with adult pneumococcal and influenza vaccinations [4].

In this paper, we report a case of a 46-year-old gentleman who recently received the inactivated (BIPP-CorV) COVID-19 vaccine and then developed fever, pancytopenia, and subsequently diagnosed with secondary HLH.

2. CASE REPORT

A 46-year-old gentleman, married, resident of Karachi, Pakistan, presented to the emergency department (ED) in our institution in the fall of May 2021 with complaints of intermittent fever for two weeks associated with chills and generalized weakness along with reduced appetite, disturbed sleep, fatigue, and weight loss. He also had shortness of breath on exertion. He had no prior medical condition. His medical and family history was also negative for any autoimmune disease. However, the patient connected the onset of symptoms after the second dose of the BBIP-CorV COVID-19 vaccine, which he had received approximately three weeks before the beginning of these symptoms. He also reported developing oral ulcers and skin rashes, especially on his hands post-vaccination, which resolved spontaneously. His COVID-19 polymerase chain reaction (PCR) was negative.

On examination, he was alert and oriented but tachypneic with a respiratory rate of 27 breaths per minute; however, he maintained oxygen saturation at 99% on room air. There were occasional left basal crepitations on chest auscultation and the rest of the systemic examination was unremarkable. Relevant
blood investigations were initially performed, and his blood picture showed a decrease in all cell lineages, as shown in table 1. Our initial differentials included; drug-induced cytopenia, sepsis, any autoimmune condition, or viral infection leading to these clinical symptoms. Peripheral blood films showed persistent pancytopenia and atypical lymphocytes. Detailed autoimmune workup and the infection screen including CMV, EBV, HIV, Hepatitis panel and Brucella serology were performed, but all investigation results were negative.

A bone marrow biopsy (BMB) was performed, which showed hypocellularity for age with overall cellularity of approximately 25%. There were megakaryocytes present along with increased histiocyte activity, with some showing hemophagocytosis and dysplasia. The Immunohistochemistry (IHC) profile demonstrated strong CD 68 positivity with overall findings suggestive of Hemophagocytic lymphohistiocytosis (Figure 01 a, b). Hence, this prompted further investigations, including fasting triglyceride levels and serum ferritin, shown in table 2. A computed tomography (CT) scan was also performed, which did not report any significant findings. A unifying diagnosis of Hemophagocytic lymphohistiocytosis (HLH) was made as our patient met the 2004 HLH-diagnostic criteria (Table 2).

We also discussed this case at our multidisciplinary board meeting, where it concurred that the patient had acquired HLH post-Covid-19 vaccination.

3. TREATMENT AND FOLLOWUP

The patient was immediately commenced on dexamethasone acetate at a dose of 10 mg/m2. His blood parameters (Figure 02) and his clinical condition continued to improve over time, and he started feeling better a few weeks after the treatment was initiated hence, no cytotoxic chemotherapy was prescribed. He continued dexamethasone 10 mg/m2 for two weeks followed by 5 mg/m2 for two weeks, 2.5 mg/m2 for the next two weeks, 1.5 mg/m2 for further one week, and then taper and discontinue during 8th week and now on close follow ups.

4. DISCUSSION

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening, hyper-inflammatory hematological disorder characterized by excessive stimulation of lymphocytes and macrophages, causing release of a large amount of pro-inflammatory cytokines [5]. Unrecognized and untreated, this rapid cellular activation culminates in progressive multi-organ failure and mortality. HLH is classified into two categories; primary (familial) and secondary (acquired) [6]. Primary HLH entails cytotoxic lymphocyte dysfunction arising from a genetic mutation [7]. The acquired form of HLH occurs from an underlying
predisposing factor such as systemic infections, malignancy, immune-mediated inflammatory diseases (IMIDs), or immunodeficiencies, in which a trigger is usually identified, leading to immune dysregulation [8]. The clinical presentation of this rare disorder varies significantly and presents a diagnostic dilemma [1]. In 2004, the Histiocyte society published clinical guidelines defining a spectrum of clinical, laboratory, and molecular mechanisms to establish a diagnostic criterion for primary and secondary HLH [9].

Most patients with secondary HLH present with fever, hepatosplenomegaly, and cytopenias, while the most common laboratory findings include deranged liver enzymes, hyperferritinemia, hypertriglyceridemia, and coagulopathy [4]. In secondary HLH, an identifiable underlying cause, e.g., acute viral infection, can help in prompt diagnosis and adequate management. The most common cause of acquired HLH includes viruses, of which the Epstein Barr virus (EBV) is the most common agent; others include the cytomegalovirus, the human-herpes-8 virus (HHV8), and the human immunodeficiency virus (HIV) [8]. Malignancies and autoimmune diseases account for the remaining causes of acquired (reactive) HLH [8]. More recently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing the coronavirus infectious disease (COVID-19), has also been reported to lead to secondary HLH [10-13]. The underlying mechanism of secondary HLH from SARS-CoV-2 results from a cytokine-storm generated through various pathways [10, 14].

Interestingly, vaccines have also been implicated in activating HLH through their immune mediating mechanisms. Ikebe et al. reported one such case, where a patient with aplastic anemia developed secondary HLH after receiving the influenza vaccine [11]. Other vaccines with such evidence include tetanus, pneumococcal, diphtheria-pertussis-tetanus, mumps-rubella, and measles vaccine [9, 10]. It is important to note that the majority of these are inactivated vaccines possibly suggesting the existence of an underlying mechanism leading to an exaggerated immune response.

Since the start of the COVID-19 pandemic, the pharmaceuticals and the scientific community all joined the race to manufacture potent vaccines to curb this global disease. One such vaccine, the BBIP-CorV COVID-19, manufactured by Sinopharm's Beijing Institute of Biological Products, has been distributed in various parts of Asia. The rapid release of different vaccines against SAR-CoV-2 has resulted in limited data on the safety profile, which remains an area of interest and further exploration.

A case report from China described a male patient diagnosed with HLH secondary to inactivated COVID-19 vaccine [15]. The patient described in this report was previously vaccinated with the BBIP-CorV vaccine and then went on to develop sudden onset of fever and pancytopenia. Interestingly, he also had evidence of EBV infection, a common cause of acquired HLH, unlike our patient's case. Attwell, Luke, et al. recently reported three cases of COVID Vaccine induced secondary HLH in patients with previously known clinical co-morbid conditions [16]. Hence in our case, given the recent history of COVID-19 vaccination, associated with the clinical and histopathological profile of HLH, and having
met five out of the eight components of the 2004 HLH trial criteria, we diagnosed our patient with acquired HLH secondary to the BBIP-CorV vaccine. To the best of our knowledge, this is the first ever case report related to HLH following the receipt of inactivated COVID-19 vaccine (BBIP-CorV) in an immunocompetent individual in our population. Our search showed one similar case of a vaccine induced HLH from the United Kingdom [17]. However, it was a recombinant vaccine (ChAdOx1 nCoV-19), unlike in our case.

A clinical trial from China, including 192 participants vaccinated with the BBIP-CorV vaccine, shows that most participants experienced fever as the most common systemic adverse effect. In contrast, most of the participants tolerated it well [18]. Glucocorticoids are the mainstay of clinical management in these patients, while cyclosporine and intravenous immunoglobulin have also improved overall survival [19]. We started our patient on dexamethasone therapy, which led to a switch-off effect on systemic inflammation and prompt clinical and laboratory profile resolution. Our experience further supports the evidence for the therapeutic role of glucocorticoids in these patients.

This report aims to highlight the association of an inactivated COVID-19 vaccine (BBIP-CorV) as a stimulus for secondary HLH. Since HLH is a diagnosis often made with a high index of suspicion, we recommend that physicians be aware of this adverse condition, as prompt diagnosis and early initiation of effective treatment for HLH are associated with improved patient outcomes.

CONCLUSION

The data from clinical trials support the general safety profile of inactivated COVID-19 vaccines. We endorse its mass implementation, as the benefits far outweigh individual risk, which seems minimal. However, we hope that robust data is required to evidence any adverse events, especially those with serious outcomes. Physicians should be aware of inactivated COVID-19 vaccine as a potential cause for HLH in the presence of suggestive clinical and laboratory criteria and start prompt treatment for improved outcome and survival.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

ACKNOWLEDGEMENTS

I would like to acknowledge and thank Mr. Salman Muhammad Soomar Research Specialist Oncology and Team of Department of Hematology and Oncology, Aga Khan University Hospital for providing data and relevant details for the case report.
REFERENCES


**Table 1:** Complete blood picture details

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb (g/dl)</td>
<td>7.5</td>
<td>7.4</td>
<td>8.9</td>
<td>8.3</td>
<td>7.1</td>
<td>9.3</td>
<td>7.8</td>
<td>8.3</td>
<td>8.5</td>
<td>8.7</td>
<td>8.4</td>
<td></td>
</tr>
<tr>
<td>HCT (%)</td>
<td>22.1</td>
<td>20.8</td>
<td>25.2</td>
<td>23.5</td>
<td>19.8</td>
<td>26.9</td>
<td>22.3</td>
<td>23.3</td>
<td>23.5</td>
<td>24.5</td>
<td>24.5</td>
<td>23.8</td>
</tr>
<tr>
<td>WBC (x10^9/l)</td>
<td>0.5</td>
<td>&lt;0.5</td>
<td>&lt;0.5</td>
<td>0.6</td>
<td>0.7</td>
<td>0.7</td>
<td>0.8</td>
<td>0.9</td>
<td>1.7</td>
<td>2.1</td>
<td>3.1</td>
<td>3</td>
</tr>
<tr>
<td>PMN (%)</td>
<td>6</td>
<td>11.1</td>
<td>7.3</td>
<td>6.6</td>
<td>12.3</td>
<td>15.4</td>
<td>29.4</td>
<td>54.1</td>
<td>52.6</td>
<td>60.9</td>
<td>56.8</td>
<td>54.4</td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
<td>NA</td>
<td>74.1</td>
<td>80.5</td>
<td>78.7</td>
<td>76.9</td>
<td>76.9</td>
<td>61.3</td>
<td>35.6</td>
<td>43.9</td>
<td>33.3</td>
<td>33.1</td>
<td>31.8</td>
</tr>
<tr>
<td>NLR</td>
<td>NA</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.2</td>
<td>0.2</td>
<td>0.5</td>
<td>1.5</td>
<td>1.2</td>
<td>1.8</td>
<td>1.7</td>
<td>1.7</td>
</tr>
<tr>
<td>Monocytes (%)</td>
<td>NA</td>
<td>11.1</td>
<td>12.2</td>
<td>13.1</td>
<td>10.8</td>
<td>7.7</td>
<td>9.3</td>
<td>10.3</td>
<td>3.5</td>
<td>5.8</td>
<td>10.1</td>
<td>13.5</td>
</tr>
<tr>
<td>MCHC (g/dl)</td>
<td>NA</td>
<td>35.6</td>
<td>36.5</td>
<td>35.3</td>
<td>35.9</td>
<td>34.6</td>
<td>35</td>
<td>35.6</td>
<td>35.3</td>
<td>34.7</td>
<td>35.5</td>
<td>35.3</td>
</tr>
<tr>
<td>Platelets (x10^9/l)</td>
<td>6</td>
<td>&lt;4</td>
<td>5</td>
<td>23</td>
<td>3</td>
<td>10</td>
<td>12</td>
<td>15</td>
<td>12</td>
<td>25</td>
<td>47</td>
<td>40</td>
</tr>
</tbody>
</table>
### Table 2: Patient investigation results and 2004 HLH diagnostic criteria

<table>
<thead>
<tr>
<th>HLH-2004 criteria: [4]</th>
<th>Patient's values</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Fever: ≥38.5C</td>
<td>39°C</td>
</tr>
<tr>
<td>2. Splenomegaly</td>
<td>No</td>
</tr>
<tr>
<td>3. Cytopenia affecting ≥ 2 lineages:</td>
<td>Yes, all three lineages (as above)</td>
</tr>
<tr>
<td>4. Hypertriglyceridemia: fasting triglycerides &gt;265 mg/dl OR hypofibrinogenemia: ≤150 mg/dl</td>
<td>Fasting TG: 274 mg/dl</td>
</tr>
<tr>
<td>5. Hemophagocytosis in bone marrow, spleen, or lymph nodes</td>
<td>Bone marrow biopsy showed increased histiocyte activity with hemophagocytosis</td>
</tr>
<tr>
<td>6. Hyperferritinemia: &gt;500 µg/l (= 500 ng/ml)</td>
<td>7068.1 ng/ml</td>
</tr>
<tr>
<td>7. Low or absent NK-cell activity</td>
<td>Test not performed</td>
</tr>
<tr>
<td>8. Elevated soluble IL-2R/CD25: ≥2,400 U/ml</td>
<td>Test not performed</td>
</tr>
</tbody>
</table>
FIGURES

Figure 1: (A, B) - Bone marrow smear showing hemophagocytosis histiocyte (arrow) with engulfed red blood cells and platelets (hemophagocytosis)

Figure 2: Improvement in blood parameters. Green: Hemoglobin, Blue: Platelets, Orange: White blood cells